BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25808075)

  • 1. Clinical picture, outcome and predictive factors of lymphoma in Sjӧgren syndrome.
    Papageorgiou A; Voulgarelis M; Tzioufas AG
    Autoimmun Rev; 2015 Jul; 14(7):641-9. PubMed ID: 25808075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial neural networks help to identify disease subsets and to predict lymphoma in primary Sjögren's syndrome.
    Baldini C; Ferro F; Luciano N; Bombardieri S; Grossi E
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):137-144. PubMed ID: 30156549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Sjӧgren's syndrome: Clinical phenotypes, outcome and the development of biomarkers.
    Goules AV; Tzioufas AG
    Autoimmun Rev; 2016 Jul; 15(7):695-703. PubMed ID: 26970487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study.
    Quartuccio L; Isola M; Baldini C; Priori R; Bartoloni Bocci E; Carubbi F; Maset M; Gregoraci G; Della Mea V; Salvin S; De Marchi G; Luciano N; Colafrancesco S; Alunno A; Giacomelli R; Gerli R; Valesini G; Bombardieri S; De Vita S
    J Autoimmun; 2014 Jun; 51():75-80. PubMed ID: 24231556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphomagenesis in Sjögren's syndrome: Predictive biomarkers towards precision medicine.
    Goules AV; Tzioufas AG
    Autoimmun Rev; 2019 Feb; 18(2):137-143. PubMed ID: 30572133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome.
    Nezos A; Papageorgiou A; Fragoulis G; Ioakeimidis D; Koutsilieris M; Tzioufas AG; Moutsopoulos HM; Voulgarelis M; Mavragani CP
    J Autoimmun; 2014 Jun; 51():89-98. PubMed ID: 23845207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome.
    Anaya JM; McGuff HS; Banks PM; Talal N
    Semin Arthritis Rheum; 1996 Apr; 25(5):337-46. PubMed ID: 8778989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome.
    Solans-Laqué R; López-Hernandez A; Bosch-Gil JA; Palacios A; Campillo M; Vilardell-Tarres M
    Semin Arthritis Rheum; 2011 Dec; 41(3):415-23. PubMed ID: 21665245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinical prediction rule for lymphoma development in primary Sjögren's syndrome.
    Baldini C; Pepe P; Luciano N; Ferro F; Talarico R; Grossi S; Tavoni A; Bombardieri S
    J Rheumatol; 2012 Apr; 39(4):804-8. PubMed ID: 22337248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.
    Papageorgiou A; Ziogas DC; Mavragani CP; Zintzaras E; Tzioufas AG; Moutsopoulos HM; Voulgarelis M
    PLoS One; 2015; 10(2):e0116189. PubMed ID: 25723713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Characteristics of the patients with primary Sjögren's syndrome complicated with lymphoma].
    Li YQ; Yu QM; Li J; Yang JR; Niu T
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 May; 43(3):467-9. PubMed ID: 22812260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematologic manifestations of primary Sjögren's syndrome.
    Manganelli P; Fietta P; Quaini F
    Clin Exp Rheumatol; 2006; 24(4):438-48. PubMed ID: 16956437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting progression to lymphoma in Sjögren's syndrome patients.
    Giannouli S; Voulgarelis M
    Expert Rev Clin Immunol; 2014 Apr; 10(4):501-12. PubMed ID: 24451006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Malignant lymphoma associated with primary Sjögren's syndrome].
    Wang L; Zhao Y; Zhang FC
    Zhonghua Yi Xue Za Zhi; 2010 Oct; 90(39):2773-5. PubMed ID: 21162916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sjögren's syndrome and non-Hodgkin's lymphoma: from pathophysiology to treatment].
    Le Guern V; Mouthon L
    Presse Med; 2011 Dec; 40(12 Pt 1):1113-9. PubMed ID: 21964038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evaluation of disease activity in Sjögren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study.
    De Vita S; Gandolfo S; Zandonella Callegher S; Zabotti A; Quartuccio L
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):150-156. PubMed ID: 30156548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic implications of mixed monoclonal cryoglobulinemia in Sjogren's disease].
    Vasil'ev VI; Probatova NA; Varlamova EIu; Tupitsin NN; Simonova MV; Safonova TN; Bozh'eva LA; Shornikova NS; Logvinenko OA; Belenin GIu
    Ter Arkh; 2004; 76(8):61-8. PubMed ID: 15471400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of three potential autoantibodies in Sjogren's syndrome and associated MALT lymphoma.
    Cui L; Elzakra N; Xu S; Xiao GG; Yang Y; Hu S
    Oncotarget; 2017 May; 8(18):30039-30049. PubMed ID: 28404907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sjögren's syndrome in patients with newly diagnosed untreated non-Hodgkin's lymphoma.
    Andonopoulos AP; Tiniakou M; Melachrinou M; Sfountouris H; Bounas A; Zervas C; Zoumbos NC
    Rev Rhum Engl Ed; 1997 May; 64(5):287-92. PubMed ID: 9190001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma.
    Baldini C; Mosca M; Della Rossa A; Pepe P; Notarstefano C; Ferro F; Luciano N; Talarico R; Tani C; Tavoni AG; Bombardieri S
    Clin Exp Rheumatol; 2013; 31(2):272-80. PubMed ID: 23343785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.